Med. praxi. 2024;21(3):135-145 | DOI: 10.36290/med.2024.018

Cystic fibrosis - diagnosis and treatment

MUDr. Eva Pokojová
Centrum cystické fibrózy, Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno
Lékařská fakulta, Masarykova univerzita, Brno

Cystic fibrosis (CF) is an inherited disease caused by a mutation in the transmembrane conductance regulator (CFTR) gene. A non-functional CFTR channel causes dysfunction of the exocrine glands resulting in a high concentration of chlorides in sweat and the accumulation of viscous secretions in the respirátory and digestive tract. Cystic fibrosis is typically a progressive respiratory disease and an impaired nutritional status of the patient due to exocrine pancreatic insufficiency. Up to 98 % of adult men are infertile due to obstructive azoospermia. The newborn screening of CF, the availability of innovative therapy with CFTR modulators (CFTRm), and the highly specialized center care lead to both the significantly improved quality of life and better prognosis of CF patients. The median survival probability for CF patients is currently 53 years. At the same time, the number of lung transplants is decreasing. On the other hand, the number of pregnancies among women with CF is increasing significantly.

Keywords: cystic fibrosis, diagnosis, treatment.

Received: February 20, 2024; Revised: May 23, 2024; Accepted: May 23, 2024; Published: June 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pokojová E. Cystic fibrosis - diagnosis and treatment. Med. praxi. 2024;21(3):135-145. doi: 10.36290/med.2024.018.
Download citation

References

  1. Castellani C, Linnane B, Pranke I, et al. Cystic Fibrosis Diagnosis in Newborns, Children, and Adults. Semin Respir Crit Care Med. 2019 Dec;40(6):701-714. Go to original source... Go to PubMed...
  2. Křenková P, Piskáčková T, Holubová A, et al. Distribution of CFTR mutations in the Czech population: Positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alieles and relevance for related/derived populations. J Cyst Fibros. 2013;12(5):532-537. Go to original source... Go to PubMed...
  3. Fila L. Cystická fibróza u dospělých. Interní med. 2014;16(2):54-60.
  4. Bonadia LC, de Lima Marson FA, Ribeiro JD, et al. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease. Gene. 2014 May 1;540(2):183-90. doi: 10.1016/j.gene.2014. 02. 040. Epub 2014 Feb 26. PMID: 24583165. Go to original source...
  5. Český registr cystické fibrózy [Internet]. Praha. Available from: http://www.cfregistr.cz.
  6. Vávrová V, et al. Cystická fibróza. Praha: Grada Publishing; 2006.
  7. Bartošová J. Novorozenecký screening cystické fibrózy a diagnostika CFSPID. Čes­‑slov Pediat. 2019;74(7):381-386.
  8. https://cftr2.orgMiddleton PG, Mall MA, Devnek P, et al; VX17-445-102 Study Group. Elexacaftor‑Tezacaftor‑Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa190863 Go to original source...
  9. Epub 2019 Oct 31. PMID: 31697873; PMCID: PMC7282384.
  10. Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519-2531. Go to original source... Go to PubMed...
  11. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee. Cystic Fibrosis Foundantion pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11:1640-1650. Go to original source... Go to PubMed...
  12. Milinic T, McElvaney OJ, Goss CH. Diagnosis and Management of Cystic Fibrosis Exacerbations. Semin Respir Crit Care Med. 2023 Apr;44(2):225-241. Go to original source... Go to PubMed...
  13. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. Go to original source... Go to PubMed...
  14. Waters V, Stanojevc S, Atenafu EG, et al. Effect of pulmonary exacerbations on long­‑term lung function decline in cystic fibrosis. Eur Respir J. 2012;40:61-66. Go to original source... Go to PubMed...
  15. Fila L, Šterclová M. Transplantace plic: kritéria pro referování k předtransplantačnímu vyšetření. Poziční dokument ČPFS ČLS JEP. Stud Pneumol Phthiseol. 2023;83:203-206.
  16. Stevens DA, Moss RB, Kurup VP, et al. Participants in the Cystic Fibrosis Foundantion Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis­‑state of the art: Cystic Fibrosis Foundantion Consensus Conference. Clin Infect, DiS. 2003;37(Suppl 3):S225-S264. Go to original source... Go to PubMed...
  17. Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous Mycobacteria. II:nested­‑cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167(6):835-840. Go to original source... Go to PubMed...
  18. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelenes: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182:298-306. Go to original source... Go to PubMed...
  19. Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S70-S78. Go to original source... Go to PubMed...
  20. Ode KL, Chan CL, Granados A, et al. Cystic fibrosis related diabetes: medical management. J Cyst Fibros. 2019;18(Suppl 2):S10-S18. Go to original source... Go to PubMed...
  21. Sellers ZM, Assis DN, Paranjape SM, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2024 May 1;79(5):1220-1238. doi: 10.1097/HEP.0000000000000646. Epub 2023 Oct 26. PMID: 37934656; PMCID: PMC11020118. Go to original source... Go to PubMed...
  22. Putman MS, Anabtawi A, Le T, et al. Cystic fibrosis bone disease treatment: Current knowledge and future directions. J Cyst Fibros. 2019;18(Suppl 2):S48-S55. Go to original source... Go to PubMed...
  23. Colombo C, Ellemunter H, Houwen R, et al. ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J cyst Fibros. 2011;10(Suppl 2):S24-S28. Go to original source... Go to PubMed...
  24. Turck D, Braegger ChP, Colombo C, et. al. ESPEN­‑ESPGHAN­‑ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clinical Nutrition. 2016;35:557-577. Go to original source... Go to PubMed...
  25. Hadjiliadis D, Khoruts A, Zauber AG, et al. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology. 2018;154:736-745. Go to original source... Go to PubMed...
  26. Bell Sc, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65-124. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.